BACKGROUND: Population-level hepatitis C virus (HCV) infection incidence is a surrogate for community drug-related risk. METHODS: We characterized trends in human immunodeficiency virus (HIV) and HCV infection incidence and HCV infection prevalence among injection drug users (IDUs) recruited over 4 periods: 1988-1989, 1994-1995, 1998, and 2005-2008. We calculated HIV and HCV infection incidence within the first year of follow-up among IDUs whose test results were negative for these viruses at baseline (n = 2061 and n = 373, respectively). We used Poisson regression to compare trends across groups. RESULTS: HIV infection incidence declined significantly from 5.5 cases/100 person-years (py) in the 1988-1989 group to 2.0 cases/100 py in the 1994-1995 group to 0 cases/100 py in the 1998 and 2005-2008 groups. Concurrently, HCV infection incidence declined but remained robust (22.0 cases/100 py in the 1988-1989 cohort to 17.2 cases/100 py in the 1994-1995 cohort, 17.9 cases/100 py in the 1998 cohort, and 7.8 cases/100 py in the 2005-2008 cohort; P = .07). Likewise, HCV infection prevalence declined, but chiefly in younger IDUs. For persons aged <39 years, relative to the 1988-1989 cohort, all groups exhibited significant declines (adjusted prevalence ratio [PR] for the 2005-08 cohort, .73; 95% confidence interval [CI], .65-.81). However, for persons aged ≥ 39 years, only the 2005-2008 cohort exhibited declining prevalence compared with the 1988-1989 cohort (adjusted PR, .87; 95% CI, .77-.99). CONCLUSIONS: Although efforts to reduce blood-borne infection incidence have had impact, this work will need to be intensified for the most transmissible viruses, such as HCV.
BACKGROUND: Population-level hepatitis C virus (HCV) infection incidence is a surrogate for community drug-related risk. METHODS: We characterized trends in human immunodeficiency virus (HIV) and HCV infection incidence and HCV infection prevalence among injection drug users (IDUs) recruited over 4 periods: 1988-1989, 1994-1995, 1998, and 2005-2008. We calculated HIV and HCV infection incidence within the first year of follow-up among IDUs whose test results were negative for these viruses at baseline (n = 2061 and n = 373, respectively). We used Poisson regression to compare trends across groups. RESULTS:HIV infection incidence declined significantly from 5.5 cases/100 person-years (py) in the 1988-1989 group to 2.0 cases/100 py in the 1994-1995 group to 0 cases/100 py in the 1998 and 2005-2008 groups. Concurrently, HCV infection incidence declined but remained robust (22.0 cases/100 py in the 1988-1989 cohort to 17.2 cases/100 py in the 1994-1995 cohort, 17.9 cases/100 py in the 1998 cohort, and 7.8 cases/100 py in the 2005-2008 cohort; P = .07). Likewise, HCV infection prevalence declined, but chiefly in younger IDUs. For persons aged <39 years, relative to the 1988-1989 cohort, all groups exhibited significant declines (adjusted prevalence ratio [PR] for the 2005-08 cohort, .73; 95% confidence interval [CI], .65-.81). However, for persons aged ≥ 39 years, only the 2005-2008 cohort exhibited declining prevalence compared with the 1988-1989 cohort (adjusted PR, .87; 95% CI, .77-.99). CONCLUSIONS: Although efforts to reduce blood-borne infection incidence have had impact, this work will need to be intensified for the most transmissible viruses, such as HCV.
Authors: Shruti H Mehta; Gregory M Lucas; Lisa B Mirel; Michael Torbenson; Yvonne Higgins; Richard D Moore; David L Thomas; Mark S Sulkowski Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Norah Palmateer; Jo Kimber; Matthew Hickman; Sharon Hutchinson; Tim Rhodes; David Goldberg Journal: Addiction Date: 2010-03-02 Impact factor: 6.526
Authors: Shruti H Mehta; Noya Galai; Jacquie Astemborski; David D Celentano; Steffanie A Strathdee; David Vlahov; Kenrad E Nelson Journal: J Acquir Immune Defic Syndr Date: 2006-11-01 Impact factor: 3.731
Authors: Holly Hagan; Mary H Latka; Jennifer V Campbell; Elizabeth T Golub; Richard S Garfein; David A Thomas; Farzana Kapadia; Steffanie A Strathdee Journal: Clin Infect Dis Date: 2006-01-20 Impact factor: 9.079
Authors: Charlotte H S B van den Berg; Colette Smit; Margreet Bakker; Ronald B Geskus; Ben Berkhout; Suzanne Jurriaans; Roel A Coutinho; Katja C Wolthers; Maria Prins Journal: Eur J Epidemiol Date: 2007-03-03 Impact factor: 8.082
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm Journal: J Virol Date: 2015-10-07 Impact factor: 5.103
Authors: Long Zhang; David D Celentano; Nguyen Le Minh; Carl A Latkin; Shruti H Mehta; Constantine Frangakis; Tran Viet Ha; Tran Thi Mo; Teerada Sripaipan; Wendy W Davis; Vu Minh Quan; Vivian F Go Journal: Eur J Gastroenterol Hepatol Date: 2015-05 Impact factor: 2.566
Authors: R Irvin; A McAdams-Mahmoud; D Hickman; J Wilson; W Fenwick; I Chen; N Irvin; O Falade-Nwulia; M Sulkowski; R Chaisson; D L Thomas; S H Mehta Journal: J Community Med Health Educ Date: 2016-05-30
Authors: Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Noya Galai; Jonathan Washington; Yvonne Higgins; Ashwin Balagopal; David L Thomas Journal: Ann Intern Med Date: 2013-05-07 Impact factor: 25.391